Rituximab at lower dose for neuromyelitis optica spectrum disorder: a multicenter, open-label, self-controlled, prospective follow-up study - Concepedia

Concepedia

Publication | Open Access

Rituximab at lower dose for neuromyelitis optica spectrum disorder: a multicenter, open-label, self-controlled, prospective follow-up study

DOI Full Paper Access

12

Citations

30

References

2023

Year

Daidi Zhao, Kaixi Ren, Jiarui Lu, Zhiqin Liu, Zunbo Li, Jun Wu, Zhihao Xu, Songdi Wu, Tao Lei, Chao Ma,

Frontiers in Immunology

Abstract

Our research provided evidence supporting the lower-dose RTX strategy in treating NMOSD and reopened the issues of optimal dosage and therapy initiation timing.

References

	Year	Citations

Page 1